Artio Medical Announces Interim Study Results Highlighting Aneurysm Occlusion Device at Neurovascular Conference

FAIRWAY, Kan., March 17, 2020 /PRNewswire/ -- Artio Medical, a medical device company developing innovative products for peripheral vascular and neurovascular diseases, announced today the recent presentation of interim nonclinical study results at the ABC-WIN Seminar in Val d’Isere, France. Presented by Dr. Blaise Baxter, a neurovascular and peripheral interventional radiologist, the interim data demonstrated that use of the Endura™ Embolization System in bifurcation aneurysms can result in greater aneurysm occlusion and lower coil prolapse into parent arteries when compared to commercially available coil-only treatments.

“The Endura Embolization Device covers the aneurysm neck and provides a platform to embolize the remainder of the aneurysm sac,” said Dr. Baxter, an investor and consultant to the Company. “I am pleased to be the first to present the Endura technology to my peers. It is exciting to have this promising option on the horizon, and I believe it has the potential to significantly improve outcomes for patients with cerebral aneurysms,” added Baxter.

The Endura Embolization System consists of a detachable accessory balloon and soft platinum coils. The combination of coils and a balloon has the potential to provide immediate cerebral aneurysm occlusion, reduce the risk of coil prolapse, and promote endothelialization of the aneurysm neck by presenting a flat, solid surface at the aneurysm neck. Funded by a Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, the study compared the efficacy of the Endura Embolization System to coil-only treatments for the occlusion of aneurysms in a challenging model of terminal bifurcation aneurysms.

“We are pleased the Endura technology was presented at this year’s ABC-WIN conference which provided an excellent opportunity to engage with physicians,” said Dr. F. Nicholas Franano, President and CEO of Artio. “Many difficult clinical cases were presented, highlighting the challenges associated with current commercially available devices. The feedback received on the Endura System was very encouraging, and we are increasingly confident in the clinical and commercial potential of Artio’s aneurysm occlusion devices.”

About Artio Medical
Artio Medical is a medical device company committed to developing innovative endovascular products for the treatment of peripheral vascular, neurovascular, and structural heart diseases. Artio’s products are designed to provide precision placement, immediate occlusion, and rapid sealing of arteries, veins, saccular aneurysms, and other blood-containing structures. For more information, please visit www.artiomedical.com.

About the Endura™ Embolization System
Cerebral aneurysms affect about 4% of the global population. There are almost 500,000 deaths worldwide each year caused by brain aneurysms, usually due to rupture and hemorrhagic stroke. Cerebral aneurysm embolization is a minimally invasive procedure that blocks or reduces blood flow into cerebral aneurysms to treat or prevent hemorrhagic stroke. Artio Medical is developing the Endura Embolization System to provide a new option for cerebral aneurysm occlusion. The system offers a unique combination of coils and a balloon designed for placement within the aneurysm sac to provide immediate aneurysm occlusion. The Endura System has three components, a detachable polymer balloon device called the Endura Embolization Accessory Device, Endura Aneurysm Coils, and Endura Balloon Coils. These components are designed to work together to cover the aneurysm neck, frame and fill the aneurysm sac, and provide immediate aneurysm occlusion while reducing the risk of coil prolapse into the parent vessel.

View original content to download multimedia:http://www.prnewswire.com/news-releases/artio-medical-announces-interim-study-results-highlighting-aneurysm-occlusion-device-at-neurovascular-conference-301025158.html

SOURCE Artio Medical, Inc.